Eli Lilly has reported promising Phase II results for lepodisiran, its experimental therapy aimed at reducing lipoprotein(a) [Lp(a)], a genetically inherited risk factor for heart disease.

April 2 (UPI) --Heart disease experts are hailing the results of a clinical trial that showed a strongly positive performance by Eli Lilly's drug lepodisiran, which inhibits the body's production ...

doctor says Elevated lipoprotein levels bring the risk of heart attacks and strokes Lepodisiran, an experimental drug from the pharmaceutical company Eli Lilly, is a small interfering RNA (siRNA ...

CHICAGO — The remarkable and sustained reductions in lipoprotein(a) ( Lp[a]) achieved with lepodisiran (Eli Lilly) , a novel small-interfering (si)RNA molecule, in a phase 2 trial might signal a ...

Eli Lilly has recently announced several developments, including positive Phase 2 results for their siRNA therapy lepodisiran and the expansion of their digital healthcare platform, LillyDirect ...

In patients with Lp(a) levels of at least 175 nmol/L, those who received the highest tested dose of lepodisiran (Eli Lilly) saw a 94% decline over 60 to 180 days compared with patients receiving ...

Lepodisiran, an experimental drug by Eli Lilly, reduces the risk of genetic heart disease by 94%. The drug significantly decreases Lp(a) levels, a genetically inherited risk for heart attacks and ...

In the race to combat dangerous cholesterol levels, Eli Lilly's approach offers a particularly attractive proposition: a single injection of Lepodisiran remains effective for six months.